Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AgomAb Therapeutics NV - ADRs representing one common share.
(NQ:
AGMB
)
6.810
+0.090 (+1.34%)
Delayed Quote
Updated: 3:30 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AgomAb Therapeutics NV - ADRs representing one common share.
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 13, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
October 08, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 01, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
September 14, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
September 11, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Participate in Upcoming Investor Conferences
September 03, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
August 06, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
June 23, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Results of Annual General Meeting
May 27, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Participate in Upcoming Conferences
May 14, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
April 23, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
From
AgomAb Therapeutics N.V.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
